Table 2.
Incidence and male-to-female rate ratios for lymphoid neoplasms by subtype among six Asian ethnic groups and Whites in five US SEER registry areas, 1996–2004
| Asian Indian/Pakistani | Chinese | Filipino | Japanese | Korean | Vietnamese | White | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphoid neoplasm subtype | No. | Rate* | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate | |
| Total lymphoid neoplasms | Male | 191 | 27.9 | 808 | 21 | 853 | 28.4 | 597 | 22.3 | 164 | 16.1 | 203 | 24.8 | 20,190 | 44.5 |
| Female | 127 | 18.7 | 643 | 14.1 | 769 | 20.3 | 592 | 16.4 | 145 | 10.3 | 162 | 19.7 | 15,610 | 28.6 | |
| IRR | 95% CI | 1.5 | 1.13–1.97 | 1.5 | 1.34–1.66 | 1.4 | 1.26–1.54 | 1.4 | 1.21–1.54 | 1.6 | 1.23–1.99 | 1.3 | 0.99–1.61 | 1.6 | 1.52–1.59 | |
| B-cell lymphoid neoplasms, total | Male | 141 | 23.3 | 644 | 16.9 | 666 | 22.4 | 487 | 17.8 | 126 | 12.9 | 164 | 20.9 | 16,284 | 35.8 |
| Female | 89 | 14.8 | 518 | 11.4 | 614 | 16.4 | 505 | 13.7 | 116 | 8.4 | 136 | 17.1 | 12,691 | 22.7 | |
| IRR | 95% CI | 1.6 | 1.14–2.17 | 1.5 | 1.32–1.68 | 1.4 | 1.22–1.53 | 1.3 | 1.14–1.48 | 1.5 | 1.16–2.01 | 1.2 | 0.94–1.59 | 1.6 | 1.54–1.62 | |
| DLBCL | Male | 39 | 5.7 | 220 | 5.7 | 237 | 7.9 | 169 | 6.1 | 48 | 5.0 | 63 | 8.8 | 4,305 | 9.3 |
| Female | 26 | 3.8 | 191 | 4.2 | 237 | 6.5 | 174 | 4.4 | 41 | 2.9 | 58 | 7.5 | 3,247 | 5.8 | |
| IRR | 95% CI | 1.5 | 0.80–2.91 | 1.4 | 1.10–1.65 | 1.2 | 1.01–1.48 | 1.4 | 1.10–1.74 | 1.7 | 1.10–2.75 | 1.2 | 0.77–1.81 | 1.6 | 1.54–1.69 | |
| Marginal zone lymphoma | Male | 11 | 1.8 | 52 | 1.4 | 55 | 1.9 | 48 | 1.7 | 10 | 1.0 | 16 | 1.6 | 786 | 1.7 |
| Female | 6 | 1.0 | 47 | 1.0 | 62 | 1.6 | 57 | 1.6 | 8 | 0.5 | 10 | 1.1 | 996 | 1.8 | |
| IRR | 95% CI | 1.8 | 0.57–6.29 | 1.3 | 0.88–2.04 | 1.2 | 0.83–1.79 | 1.1 | 0.70–1.64 | 1.9 | 0.65–5.67 | 1.5 | 0.60–4.15 | 1.0 | 0.87–1.06 | |
| Follicular lymphoma | Male | 11 | 2.0 | 65 | 1.7 | 37 | 1.2 | 55 | 2.0 | 10 | 0.9 | 25 | 2.8 | 1,893 | 4.0 |
| Female | 13 | 2.2 | 52 | 1.1 | 37 | 0.9 | 85 | 2.5 | 14 | 1.0 | 9 | 1.0 | 1,895 | 3.5 | |
| IRR | 95% CI | 0.9 | 0.32–2.46 | 1.5 | 1.04–2.25 | 1.3 | 0.77–2.05 | 0.8 | 0.57–1.19 | 0.9 | 0.34–2.27 | 3.0 | 1.23–8.08 | 1.2 | 1.08–1.23 | |
| CLL/SLL** | Male | 21 | 3.6 | 72 | 1.9 | 43 | 1.4 | 34 | 1.2 | 6 | 0.8 | 7 | 1.1 | 3,469 | 7.7 |
| Female | 10 | 2.3 | 40 | 0.9 | 29 | 0.8 | 19 | 0.5 | 6 | 0.4 | 8 | 1.0 | 2,461 | 4.2 | |
| IRR | 95% CI | 1.6 | 0.67–4.30 | 2.2 | 1.44–3.26 | 1.8 | 1.07–2.97 | 2.3 | 1.20–4.35 | 1.9 | 0.46–6.99 | 1.1 | 0.28–3.73 | 1.8 | 1.74–1.93 | |
| Mantle cell lymphoma | Male | <5 | - | 10 | 0.3 | 20 | 0.7 | 10 | 0.4 | <5 | - | <5 | - | 478 | 1.0 |
| Female | <5 | - | 6 | 0.1 | 10 | 0.2 | 9 | 0.2 | <5 | - | <5 | - | 220 | 0.4 | |
| IRR | 95% CI | - | - | 2.0 | 0.65–6.73 | 2.8 | 1.24–6.72 | 1.9 | 0.61–5.38 | - | - | - | - | 2.7 | 2.25–3.14 | |
| Burkitt lymphoma/leukemia | Male | <5 | - | 18 | 0.4 | 22 | 0.6 | 7 | 0.4 | 5 | 0.5 | 5 | 0.6 | 279 | 0.6 |
| Female | <5 | - | 8 | 0.2 | 6 | 0.2 | 6 | 0.2 | <5 | - | <5 | - | 101 | 0.2 | |
| IRR | 95% CI | - | - | 2.3 | 0.94–6.14 | 3.5 | 1.38–10.8 | 92.5 | 0.59–9.46 | - | - | - | - | 3.1 | 2.46–3.98 | |
| Plasma cell neoplasms | Male | 30 | 6.7 | 107 | 2.9 | 155 | 5.4 | 85 | 3.0 | 22 | 2.2 | 23 | 3.4 | 2,921 | 6.5 |
| Female | 19 | 3.5 | 99 | 2.2 | 156 | 4.2 | 80 | 2.1 | 25 | 1.9 | 27 | 4.0 | 2,312 | 4.0 | |
| IRR | 95% CI | 1.9 | 0.97–3.80 | 1.3 | 1.00–1.78 | 1.3 | 1.03–1.64 | 1.4 | 1.03–2.00 | 1.2 | 0.60–2.21 | 0.9 | 0.45–1.62 | 1.6 | 1.53–1.71 | |
| Other B-cell neoplasms† | Male | 5 | 0.6 | 73 | 2.0 | 77 | 2.7 | 61 | 2.2 | 9 | 1.1 | 8 | 0.9 | 1,720 | 3.7 |
| Female | 5 | 1.2 | 49 | 1.1 | 54 | 1.5 | 59 | 1.6 | 9 | 0.7 | 9 | 1.0 | 1,135 | 2.0 | |
| IRR | 95% CI | 0.5 | 0.10–2.73 | 1.8 | 1.26–2.72 | 1.9 | 1.29–2.70 | 1.4 | 0.91–2.03 | 1.7 | 0.56–4.85 | 0.9 | 0.26–2.89 | 1.9 | 1.74–2.03 | |
| T/NK-cell lymphoid neoplasms, total | Male | 23 | 2.3 | 70 | 1.8 | 84 | 2.8 | 55 | 2.1 | 19 | 1.5 | 19 | 1.9 | 1,234 | 2.7 |
| Female | 14 | 1.2 | 52 | 1.1 | 57 | 1.4 | 43 | 1.3 | 15 | 1.0 | 14 | 1.2 | 809 | 1.6 | |
| IRR | 95% CI | 1.9 | 0.75–4.53 | 1.6 | 1.08–2.31 | 1.9 | 1.35–2.76 | 1.7 | 1.05–2.60 | 1.5 | 0.70–3.26 | 1.5 | 0.67–3.44 | 1.7 | 1.59–1.91 | |
| MF/Sézary syndrome | Male | 7 | 0.6 | 16 | 0.4 | 15 | 0.5 | 10 | 0.3 | <5 | - | <5 | - | 395 | 0.8 |
| Female | 6 | 0.4 | 15 | 0.3 | 11 | 0.3 | 8 | 0.3 | <5 | - | <5 | - | 268 | 0.5 | |
| IRR | 95% CI | 1.3 | 0.25–5.84 | 1.2 | 0.56–2.70 | 2.0 | 0.85–4.83 | 1.2 | 0.40–3.95 | - | - | - | - | 1.7 | 1.41–1.95 | |
| Peripheral T-cell lymphoma | Male | 9 | 1.2 | 19 | 0.5 | 40 | 1.3 | 30 | 1.1 | 9 | 0.7 | 8 | 0.6 | 403 | 0.9 |
| Female | <5 | - | 18 | 0.4 | 33 | 0.8 | 24 | 0.6 | 6 | 0.4 | 5 | 0.5 | 302 | 0.6 | |
| IRR | 95% CI | - | - | 1.2 | 0.61–2.50 | 1.6 | 0.97–2.62 | 1.8 | 0.96–3.29 | 1.8 | 0.53–6.34 | 1.4 | 0.37–6.13 | 1.6 | 1.33–1.82 | |
| T/NK-cell lymphoid neoplasms, NOS | Male | <5 | - | 20 | 0.5 | 19 | 0.6 | 11 | 0.5 | 6 | 0.5 | <5 | - | 259 | 0.6 |
| Female | <5 | - | 14 | 0.3 | 9 | 0.2 | 6 | 0.2 | <5 | - | <5 | - | 161 | 0.3 | |
| IRR | 95% CI | - | - | 1.8 | 0.84–3.76 | 2.5 | 1.08–6.51 | 2.4 | 0.75–8.18 | - | - | - | - | 1.8 | 1.51–2.27 | |
| Lymphoblastic leukemia/lymphoma | Male | 28 | 2.6 | 59 | 1.5 | 40 | 1.1 | 31 | 1.6 | 22 | 1.7 | 19 | 1.9 | 741 | 1.9 |
| Female | 12 | 1.1 | 41 | 0.9 | 35 | 0.9 | 28 | 1.2 | 14 | 1.0 | 13 | 1.2 | 538 | 1.4 | |
| IRR | 95% CI | 2.4 | 1.00–5.91 | 1.6 | 1.06–2.48 | 1.2 | 0.74–1.94 | 1.4 | 0.76–2.46 | 1.6 | 0.79–3.55 | 1.6 | 0.67–3.89 | 1.4 | 1.23–1.54 | |
| Hodgkin lymphoma | Male | 17 | 1.3 | 45 | 1.0 | 52 | 1.5 | 21 | 1.0 | 7 | 0.6 | 14 | 1.1 | 1,624 | 3.6 |
| Female | 19 | 1.7 | 32 | 0.7 | 65 | 1.5 | 21 | 0.7 | 8 | 0.5 | 6 | 0.6 | 1,325 | 3.0 | |
| IRR | 95% CI | 0.8 | 0.35–1.86 | 1.5 | 0.94–2.48 | 0.9 | 0.64–1.40 | 1.3 | 0.65–2.63 | 1.2 | 0.34–3.91 | 1.9 | 0.65–6.68 | 1.2 | 1.12–1.3 | |
| Other/unknown type lymphoid neoplasms‡ | Male | <5 | - | 32 | 0.8 | 41 | 1.5 | 25 | 1.0 | 6 | 0.7 | <5 | - | 917 | 2.0 |
| Female | <5 | - | 31 | 0.7 | 25 | 0.7 | 16 | 0.4 | 5 | 0.3 | <5 | - | 649 | 1.1 | |
| IRR | 95% CI | - | - | 1.2 | 0.71–2.07 | 2.1 | 1.22–3.59 | 2.5 | 1.18–5.09 | 2.0 | 0.48–8.44 | - | - | 1.9 | 1.72–2.11 | |
All incidence rates are age-adjusted to the 2000 US standard population and expressed per 100,000 person-years; Population person-years (Female & Male): Asian Indian/Pakistani (1,023,190 & 1,191,513); Chinese (4,626,477 & 4,276,140); Filipino (4,144,964 & 3,702,246); Japanese (2,349,735 & 2,041,523); Korean (1,598,784 & 1,352,890); Vietnamese (1,226,676 & 1,239,723); White (44,400,755 & 43,942,410); Counts and rates for Asian Indian/Pakistani and Vietnamese do not include data from the Hawaii SEER registry.
Abbreviations (alphabetical): chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); diffuse large B-cell lymphoma; (DLBCL); natural killer (NK); not otherwise specified (NOS); Surveillance, Epidemiology, and End Results (SEER).
Other B-cell neoplasms combines Hairy cell leukemia, lymphoblastic leukemia, Waldenstrom, and B-cell NOS
Other/unknown type lymphoid neoplasms includes prolymphocytic leukemia
-’ Statistic was not calculated because fewer than five cases were reported